ALT

Altimmune, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website altimmune.com
Employees(FY) 52
ISIN US02155H2004

Performance

-15.17%

+17.01%

+6.76%

+0.5%

-28.44%

YTD

+206.08%

Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Advanced Technical Analysis

Technical Analysis of ALT 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ALT

Stock Rank

Recent News & Updates

2024-11-15 11:00
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024(GlobeNewswire)
2024-11-14 22:00
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024(Globenewswire)
2024-11-14 06:15
Altimmune Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-11-12 07:00
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update(GlobeNewswire)
2024-11-11 18:00
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-11-11 07:30
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-11 07:30
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer(GlobeNewswire)
2024-11-10 18:30
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer(Globenewswire)
2024-11-10 18:30
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-07 07:30
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity(GlobeNewswire)
2024-11-06 18:30
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity(Globenewswire)
2024-11-06 07:30
Altimmune to Participate at Two Upcoming Investor Conferences(GlobeNewswire)
2024-11-05 18:30
Altimmune to Participate at Two Upcoming Investor Conferences(Globenewswire)
2024-11-04 07:30
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024(GlobeNewswire)
2024-11-03 18:30
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024(Globenewswire)
2024-10-15 08:00
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024(GlobeNewswire)
2024-10-14 20:00
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024(Globenewswire)
2024-10-01 07:30
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference(GlobeNewswire)
2024-09-30 19:30
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference(Globenewswire)
2024-09-30 07:30
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)(GlobeNewswire)
2024-09-29 19:30
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)(Globenewswire)
2024-09-10 13:09
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-10 07:45
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-10 01:09
CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-09-09 19:45
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-09-03 07:30
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes(GlobeNewswire)
2024-09-02 19:30
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes(Globenewswire)
2024-08-10 09:03
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags(Simply Wall St.)
2024-08-08 07:00
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update(GlobeNewswire)
2024-08-07 19:00
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.